论文部分内容阅读
目的评价阿魏酸哌嗪联合厄贝沙坦治疗糖尿病肾病的临床疗效及安全性。方法将74例糖尿病肾病患者随机分为试验组37例和对照组37例。对照组予以口服厄贝沙坦150 mg,每天一次;试验组在对照组基础上,加用口服阿魏酸哌嗪150 mg,每天一次。2组患者疗程均为12周。观察2组患者的临床疗效、血清肌酸酐、血糖、血尿素氮、尿白蛋白排泄率、血流动力学指标,以及不良反应发生情况。结果治疗后,试验组的总有效率94.59%显著高于对照组75.68%(P<0.05)。治疗后,试验组的血清肌酸酐、尿白蛋白排泄率、血流动力学指标改善程度显著优于对照组(P<0.05)。2组患者治疗前后的血糖、血尿素氮水平比较差异无统计学意义(P>0.05)。2组患者均出现不同程度的恶心、呕吐、腹痛、头晕等不良症状,经对症处理后好转,但组间比较差异无统计学意义(P>0.05)。结论阿魏酸哌嗪联合厄贝沙坦治疗糖尿病肾病的临床疗效确切,能改善肾血流动力学,保护肾功能,降低尿蛋白水平。
Objective To evaluate the clinical efficacy and safety of piperazine ferulate in combination with irbesartan in the treatment of diabetic nephropathy. Methods 74 patients with diabetic nephropathy were randomly divided into experimental group (37 cases) and control group (37 cases). The control group was given oral irbesartan 150 mg once daily. The experimental group was given oral 150 mg piperacil ferroute once a day on the basis of the control group. Two groups of patients were treated for 12 weeks. The clinical efficacy, serum creatinine, blood glucose, blood urea nitrogen, urinary albumin excretion rate, hemodynamic indexes and adverse reactions were observed in two groups. Results After treatment, the total effective rate 94.59% in the experimental group was significantly higher than that in the control group 75.68% (P <0.05). After treatment, the experimental group serum creatinine, urinary albumin excretion rate, hemodynamic improvement was significantly better than the control group (P <0.05). There was no significant difference in blood glucose and blood urea nitrogen between the two groups before and after treatment (P> 0.05). The patients in 2 groups showed different degrees of nausea, vomiting, abdominal pain, dizziness and other adverse symptoms. After symptomatic treatment, they showed no significant difference (P> 0.05). Conclusion The combination of ferulic acid piperazine and irbesartan in the treatment of diabetic nephropathy has definite curative effect, which can improve renal hemodynamics, protect renal function and lower urinary protein.